1,2-二甲基吲哚-3-乙酸 | 2597-28-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 1,2-二甲基吲哚-3-乙酸
• 英文名称: 1,2-dimethylindole-3-acetic acid
• 英文别名: 2-(1,2-dimethyl-1H-indol-3-yl)acetic acid；(1,2-Dimethyl-1H-indol-3-yl)-acetic acid；2-(1,2-dimethylindol-3-yl)acetic acid
• CAS: 2597-28-6
• 化学式: C₁₂H₁₃NO₂
• 分子量: 203.241
• InChiKey: BABSBBRYDTZWQB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  42.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1,2-二甲基吲哚-3-乙酸 生成 1,2,3-三甲基-1H-吲哚
  参考文献：
  名称：

  Degen, Justus Liebigs Annalen der Chemie, 1886, vol. 236, p. 158

  摘要：

  DOI：
• 作为产物：
  描述：

  4-(methyl-phenyl-hydrazono)-valeric acid ethyl ester 在 zinc(II) chloride 作用下， 生成 1,2-二甲基吲哚-3-乙酸
  参考文献：
  名称：

  Degen, Justus Liebigs Annalen der Chemie, 1886, vol. 236, p. 158

  摘要：

  DOI：

文献信息

• CHEMICAL SUBSTANCES WHICH INHIBIT THE ENZYMATIC ACTIVITY OF HUMAN KALLIKREIN-RELATED PEPTIDASE 6 (KLK6)
  申请人：Deutsches Krebsforschungszentrum

  公开号：EP3305781A1

  公开（公告）日：2018-04-11

  The invention relates to compounds which are suitable for the treatment of a disease associated with kallikrein-like peptidase 6 overexpression and to pharmaceutical compositions containing such compounds. The invention further relates to a kit of parts comprising such compounds or pharmaceutical compositions.

  这项发明涉及适用于治疗与kallikrein样肽酶6过度表达相关疾病的化合物，以及含有这些化合物的药物组合物。该发明还涉及包括这些化合物或药物组合物的配套工具包。
• [EN] NOVEL N-(2,3-DIHYDRO-1H-PYRROLO[2,3-B]JPYRIDIN-5-YL)-4- QUINAZOLINAMINE AND N-(2,3-DIHYDRO-1H-INDOL-5-YL)-4- QUINAZOLINAMINE DERIVATIVES AS PERK INHIBITORS<br/>[FR] DÉRIVÉS N-(2,3-DIHYDRO-1H-PYRROLO[2,3-B]PYRIDIN-5-YL)-4-QUINAZOLINAMINE ET N-(2,3-DIHYDRO-1H-INDOL-5-YL)-4-QUINAZOLINAMINE D'UN NOUVEAU TYPE EN TANT QU'INHIBITEURS DE PERK
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2014161808A1

  公开（公告）日：2014-10-09

  The present invention relates to N-(2,3-dihydro-1H-pyrrolo[2,3-b)]pyridin-5-yl)-4-quinazolinamine and N-(2.3-dihydro-1H-indol-5-yl)-4-quinazolinamine derivatives of Formula (I) wherein R1, R2, R3, R4, R5, R6 and A have the meaning defined in the claims. The compounds according to the present invention are useful as inhibitors of PERK. The invention further relates to processes for preparing such compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

  本发明涉及Formula (I)中的N-(2,3-二氢-1H-吡咯[2,3-b)]吡啶-5-基)-4-喹唑啉胺和N-(2.3-二氢-1H-吲哚-5-基)-4-喹唑啉胺衍生物，其中R1、R2、R3、R4、R5、R6和A的含义如索赔中所定义。根据本发明的化合物可用作PERK的抑制剂。本发明还涉及制备这些化合物的方法、包含上述化合物作为活性成分的药物组合物以及将上述化合物用作药物的用途。
• Synthesis of functionalized pyrroloindolines<i>via</i>a visible-light-induced radical cascade reaction: rapid synthesis of (±)-flustraminol B
  作者：Kui Wu、Yuliu Du、Zheng Wei、Ting Wang

  DOI：10.1039/c8cc03575j

  日期：——

  visible-light-induced synthesis of functionalized pyrroloindolines via a radical cascade reaction is reported. The reaction shows a broad substrate scope and highlights the mild nature of the reaction conditions. A range of substitutions on indole aromatic rings and N-centers is well tolerated, including a free allylic alcohol. Relying on the strategy, a rapid synthesis of (±)-flustraminol B was achieved.

  报道了通过自由基级联反应的可见光诱导的功能化吡咯并吲哚啉合成的发展。该反应显示出较宽的底物范围并突出了反应条件的温和性质。吲哚芳族环和N-中心的一系列取代均被很好地耐受，包括游离的烯丙醇。依靠该策略，实现了（±）-氟雌醇B的快速合成。
• Nickel-catalyzed decarboxylative cross-coupling of indole-3-acetic acids with aryl bromides by convergent paired electrolysis
  作者：Zhen-Hua Wang、Lei Wei、Ke-Jin Jiao、Cong Ma、Tian-Sheng Mei

  DOI：10.1039/d2cc02641d

  日期：——

  Herein, nickel-catalyzed decarboxylative cross-coupling of indole-3-acetic acids with aryl bromides by convergent paired electrolysis was developed in an undivided cell. This protocol features good functional group tolerance, and is chemical redox agent- and sacrificial electrode-free. Mechanistic studies indicated that the base was crucial for the decarboxylation step and a NiI/NiIII catalytic cycle

  在此，在未分裂的电池中开发了镍催化的吲哚-3-乙酸与芳基溴化物的会聚配对电解脱羧交叉偶联反应。该协议具有良好的官能团耐受性，并且不含化学氧化还原剂和牺牲电极。机理研究表明，碱对脱羧步骤至关重要，并且 Ni I /Ni III催化循环参与了这一转变。
• 1-Indolylalkyl-4-(substituted-pyridinyl)piperazines
  申请人：Bristol-Myers Squibb Company

  公开号：EP0345808A1

  公开（公告）日：1989-12-13

  A compound of Formula I and the pharmaceutically acceptable acid addition salts thereof, wherein R1 and R2 are independently selected from lower, meaning C1-4, alkyl or hydrogen; R3, R4, R8 and R9 are independently selected from hydrogen, lower alkyl, lower alkoxy, carbamide, halogen, trifluoromethyl and thio-lower alkyl, with the proviso that R8 and R9 cannot both be hydrogen at the same time; A is a Cs-7 cycloalkanyl or cycloalkenyl ring, or A is wherein n is an integer from 1 to 3 and R5 is the same as R1; and R6 and R7 are independently selected from hydrogen, methyl or R6 and R7 can be taken together as a methylene bridge, useful as antidepressants.

  式 I 的化合物及其药学上可接受的酸加成盐、 其中 R1 和 R2 独立选自低级（即 C1-4）烷基或氢； R3、R4、R8 和 R9 独立选自氢、低级烷基、低级烷氧基、碳酰胺、卤素、三氟甲基和硫代低级烷基，但 R8 和 R9 不能同时为氢； A 是 Cs-7 环烷基或环烷烯基环，或 A 是 其中 n 为 1 至 3 的整数，R5 与 R1 相同；以及 R6 和 R7 分别独立地选自氢、甲基或 R6 和 R7 可一起作为亚甲基桥，可用作抗抑郁剂。